Associated High Confidence AOPs |
---|
AOP Identifier | AOP Title | AO Classification | OECD Status | Coverage Score | KE Identifier | KE Name |
---|---|---|---|---|---|---|
AOP:4 | Ecdysone receptor agonism leading to incomplete ecdysis associated mortality | Unclassified | - | 0.1 | KE:993 | Decrease, Abdominal muscle contraction |
AOP:7 | Aromatase (Cyp19a1) reduction leading to impaired fertility in adult female | Reproductive System Disease; Endocrine System Disease; Reproductive System Disease | Under Review | 0.2 | KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
AOP:15 | Alkylation of DNA in male pre-meiotic germ cells leading to heritable mutations | Genetic Disease | WPHA/WNT Endorsed | 0.25 | KE:155 | Inadequate DNA repair |
AOP:18 | PPARα activation in utero leading to impaired fertility in males | Reproductive System Disease | Under Review | 0.12 | KE:413 | Reduction, Testosterone synthesis in Leydig cells |
AOP:21 | Aryl hydrocarbon receptor activation leading to early life stage mortality, via increased COX-2 | Unclassified | WPHA/WNT Endorsed | 0.2 | KE:317 | Altered, Cardiovascular development/function |
AOP:23 | Androgen receptor agonism leading to reproductive dysfunction (in repeat-spawning fish) | Unclassified | WPHA/WNT Endorsed | 0.2 | KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
KE:274 | Reduction, Testosterone synthesis by ovarian theca cells | |||||
AOP:25 | Aromatase inhibition leading to reproductive dysfunction | Unclassified | WPHA/WNT Endorsed | 0.12 | KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
AOP:27 | Cholestatic Liver Injury induced by Inhibition of the Bile Salt Export Pump (ABCB11) | Gastrointestinal System Disease | Under Development | 0.25 | KE:149 | Increase, Inflammation |
KE:1115 | Increase, Reactive oxygen species | |||||
AOP:39 | Covalent Binding, Protein, leading to Increase, Allergic Respiratory Hypersensitivity Response | Respiratory System Disease | Under Development | 0.2 | KE:272 | Activation/Proliferation, T-cells |
AOP:40 | Covalent Protein binding leading to Skin Sensitisation | Integumentary System Disease | WPHA/WNT Endorsed | 0.2 | KE:272 | Activation/Proliferation, T-cells |
AOP:41 | Sustained AhR Activation leading to Rodent Liver Tumours | Cancer; Gastrointestinal System Disease | Under Review | 0.6 | KE:854 | Alterations, Cellular proliferation / hyperplasia |
KE:853 | Changes/Inhibition, Cellular Homeostasis and Apoptosis | |||||
KE:139 | N/A, Hepatotoxicity, Hepatopathy, including a constellation of observable effects | |||||
AOP:58 | NR1I3 (CAR) suppression leading to hepatic steatosis | Gastrointestinal System Disease; Inherited Metabolic Disorder | - | 0.06 | KE:454 | Increased, Triglyceride formation |
AOP:60 | NR1I2 (Pregnane X Receptor, PXR) activation leading to hepatic steatosis | Gastrointestinal System Disease; Inherited Metabolic Disorder | - | 0.08 | KE:454 | Increased, Triglyceride formation |
AOP:64 | Glucocorticoid Receptor (GR) Mediated Adult Leydig Cell Dysfunction Leading to Decreased Male Fertility | Reproductive System Disease | - | 0.29 | KE:413 | Reduction, Testosterone synthesis in Leydig cells |
KE:496 | Increased apoptosis, decreased fetal/adult Leydig Cells | |||||
AOP:69 | Modulation of Adult Leydig Cell Function Subsequent to Decreased Cholesterol Synthesis or Transport in the Adult Leydig Cell | Reproductive System Disease | - | 0.2 | KE:645 | Decreased Cholesterol, Decreased Testosterone Production by Adult Leydig Cells |
AOP:77 | Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony death/failure 1 | Unclassified | - | 0.14 | KE:341 | Impairment, Learning and memory |
AOP:78 | Nicotinic acetylcholine receptor activation contributes to abnormal role change within the worker bee caste leading to colony death failure 1 | Unclassified | - | 0.12 | KE:341 | Impairment, Learning and memory |
AOP:80 | Nicotinic acetylcholine receptor activation contributes to accumulation of damaged mitochondrial DNA and leads to colony loss/failure | Unclassified | - | 0.12 | KE:664 | Overwhelmed, Mitochondrial DNA repair mechanisms |
AOP:87 | Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony loss/failure | Unclassified | - | 0.12 | KE:341 | Impairment, Learning and memory |
AOP:88 | Nicotinic acetylcholine receptor activation contributes to abnormal foraging and leads to colony loss/failure via abnormal role change within caste | Unclassified | - | 0.14 | KE:341 | Impairment, Learning and memory |
AOP:89 | Nicotinic acetylcholine receptor activation followed by desensitization contributes to abnormal foraging and directly leads to colony loss/failure | Unclassified | - | 0.12 | KE:341 | Impairment, Learning and memory |
AOP:90 | Nicotinic acetylcholine receptor activation contributes to abnormal roll change within the worker bee caste leading to colony loss/failure 2 | Unclassified | - | 0.12 | KE:341 | Impairment, Learning and memory |
AOP:96 | Axonal sodium channel modulation leading to acute mortality | Unclassified | - | 0.17 | KE:602 | Increased, Ataxia, paralysis, or hyperactivity |
AOP:99 | Histamine (H2) receptor antagonism leading to reduced survival | Unclassified | - | 0.14 | KE:341 | Impairment, Learning and memory |
AOP:105 | Alpha2u-microglobulin cytotoxicity leading to renal tubular adenomas and carcinomas (in male rat) | Cancer; Urinary System Disease | - | 0.17 | KE:710 | Increase, Regenerative cell proliferation (tubular epithelial cells) |
AOP:109 | Cytotoxicity leading to bronchioloalveolar adenomas and carcinomas (in mouse) | Cancer; Respiratory System Disease | - | 0.2 | KE:734 | Increase, Regenerative cell proliferation (terminal bronchiolar epithelial cells) |
AOP:110 | Inhibition of iodide pump activity leading to follicular cell adenomas and carcinomas (in rat and mouse) | Cancer; Endocrine System Disease | - | 0.29 | KE:277 | Thyroid hormone synthesis, Decreased |
KE:739 | Increase, Hypertrophy and proliferation (follicular cell) | |||||
AOP:113 | Glutamate-gated chloride channel activation leading to acute mortality | Unclassified | - | 0.17 | KE:764 | N/A, Ataxia, paralysis, or hyperactivity |
AOP:114 | HPPD inhibition leading to corneal papillomas and carcinomas (in rat) | Cancer | - | 0.33 | KE:777 | Increase, Inflammation (corneal cells) |
KE:778 | Increase, Regenerative cell proliferation (corneal cells) | |||||
AOP:115 | Epithelial cytotoxicity leading to forestomach tumors (in mouse and rat) | Cancer | - | 0.4 | KE:149 | Increase, Inflammation |
KE:781 | Increase, Regenerative cell proliferation (forestomach epithelial cells) | |||||
AOP:116 | Cytotoxicity leading to renal tubular adenomas and carcinomas (in male rat) | Cancer; Urinary System Disease | - | 0.25 | KE:710 | Increase, Regenerative cell proliferation (tubular epithelial cells) |
AOP:119 | Inhibition of thyroid peroxidase leading to follicular cell adenomas and carcinomas (in rat and mouse) | Cancer; Endocrine System Disease | - | 0.29 | KE:277 | Thyroid hormone synthesis, Decreased |
KE:739 | Increase, Hypertrophy and proliferation (follicular cell) | |||||
AOP:122 | Prolyl hydroxylase inhibition leading to reproductive dysfunction via increased HIF1 heterodimer formation | Unclassified | - | 0.1 | KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
AOP:123 | Unknown MIE leading to reproductive dysfunction via increased HIF-1alpha transcription | Unclassified | - | 0.09 | KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
AOP:136 | Intracellular Acidification Induced Olfactory Epithelial Injury Leading to Site of Contact Nasal Tumors | Benign Neoplasm; Respiratory System Disease | Under Review | 0.29 | KE:768 | Increase, Cytotoxicity |
KE:870 | Increase, Cell Proliferation | |||||
AOP:144 | Endocytic lysosomal uptake leading to liver fibrosis | Gastrointestinal System Disease | Under Review | 0.11 | KE:1493 | Increased Pro-inflammatory mediators |
AOP:149 | Peptide Oxidation Leading to Hypertension | Cardiovascular System Disease | Under Development | 0.2 | KE:927 | KE1 : S-Glutathionylation, eNOS |
KE:933 | KE6 : Depletion, Nitric Oxide | |||||
AOP:150 | Aryl hydrocarbon receptor activation leading to early life stage mortality, via reduced VEGF | Unclassified | WPHA/WNT Endorsed | 0.14 | KE:317 | Altered, Cardiovascular development/function |
AOP:159 | Thyroperoxidase inhibition leading to increased mortality via reduced anterior swim bladder inflation | Unclassified | WPHA/WNT Endorsed | 0.12 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:164 | Beta-2 adrenergic agonist activity leading to mesovarian leiomyomas in the rat and mouse | Cancer; Reproductive System Disease | - | 0.17 | KE:1042 | Proliferation/Clonal Expansion, smooth muscle |
AOP:167 | Early-life estrogen receptor activity leading to endometrial carcinoma in the mouse. | Reproductive System Disease; Cancer | - | 0.14 | KE:1067 | Proliferation/Clonal Expansion, aberrant basal cells |
AOP:173 | Substance interaction with the pulmonary resident cell membrane components leading to pulmonary fibrosis | Musculoskeletal System Disease; Respiratory System Disease | WPHA/WNT Endorsed | 0.12 | KE:1497 | Increased, recruitment of inflammatory cells |
AOP:175 | Thyroperoxidase inhibition leading to altered amphibian metamorphosis | Unclassified | - | 0.25 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:176 | Sodium Iodide Symporter (NIS) Inhibition leading to altered amphibian metamorphosis | Unclassified | - | 0.2 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:188 | Iodotyrosine deiodinase (IYD) inhibition leading to altered amphibian metamorphosis | Unclassified | - | 0.2 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:192 | Pendrin inhibition leading to altered amphibian metamorphosis | Unclassified | - | 0.25 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:193 | Dual oxidase (DUOX) inhibition leading to altered amphibian metamorphosis | Unclassified | - | 0.25 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:206 | Peroxisome proliferator-activated receptors γ inactivation leading to lung fibrosis | Musculoskeletal System Disease; Respiratory System Disease | Under Development | 0.17 | KE:149 | Increase, Inflammation |
AOP:207 | NADPH oxidase and P38 MAPK activation leading to reproductive failure in Caenorhabditis elegans | Reproductive System Disease | - | 0.38 | KE:1281 | Increased, DNA Damage-Repair |
KE:1115 | Increase, Reactive oxygen species | |||||
KE:1262 | Apoptosis | |||||
AOP:212 | Histone deacetylase inhibition leading to testicular atrophy | Reproductive System Disease | WPHA/WNT Endorsed | 0.5 | KE:1262 | Apoptosis |
KE:1503 | Histone acetylation, increase | |||||
KE:1505 | Cell cycle, disrupted | |||||
AOP:213 | Inhibition of fatty acid beta oxidation leading to nonalcoholic steatohepatitis (NASH) | Gastrointestinal System Disease; Inherited Metabolic Disorder | - | 0.17 | KE:1115 | Increase, Reactive oxygen species |
AOP:218 | Inhibition of CYP7B activity leads to decreased reproductive success via decreased locomotor activity | Unclassified | - | 0.17 | KE:1141 | Decreased, Reproductive Success |
AOP:219 | Inhibition of CYP7B activity leads to decreased reproductive success via decreased sexual behavior | Unclassified | - | 0.17 | KE:1141 | Decreased, Reproductive Success |
AOP:245 | Reduction in photophosphorylation leading to growth inhibition in aquatic plants | Unclassified | - | 0.09 | KE:40 | Decrease, Mitochondrial ATP production |
AOP:271 | Inhibition of thyroid peroxidase leading to impaired fertility in fish | Unclassified | Under Development | 0.2 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:272 | Deposition of energy leading to lung cancer | Cancer | WPHA/WNT Endorsed | 0.29 | KE:870 | Increase, Cell Proliferation |
KE:155 | Inadequate DNA repair | |||||
AOP:275 | Histone deacetylase inhibition leads to neural tube defects | Neural Tube Defect | - | 0.2 | KE:1503 | Histone acetylation, increase |
AOP:280 | α-diketone-induced bronchiolitis obliterans | Musculoskeletal System Disease; Respiratory System Disease | - | 0.14 | KE:149 | Increase, Inflammation |
AOP:286 | Mitochondrial complex III antagonism leading to growth inhibition (1) | Unclassified | - | 0.5 | KE:1821 | Decrease, Cell proliferation |
KE:1771 | Decrease, Adenosine triphosphate pool | |||||
AOP:287 | Mitochondrial complex III antagonism leading to growth inhibition (2) | Unclassified | - | 0.25 | KE:1771 | Decrease, Adenosine triphosphate pool |
AOP:290 | Mitochondrial ATP synthase antagonism leading to growth inhibition (1) | Unclassified | - | 0.5 | KE:1821 | Decrease, Cell proliferation |
KE:1771 | Decrease, Adenosine triphosphate pool | |||||
AOP:291 | Mitochondrial ATP synthase antagonism leading to growth inhibition (2) | Unclassified | - | 0.25 | KE:1771 | Decrease, Adenosine triphosphate pool |
AOP:296 | Oxidative DNA damage leading to chromosomal aberrations and mutations | Genetic Disease; Chromosomal Disease | WPHA/WNT Endorsed | 0.2 | KE:155 | Inadequate DNA repair |
AOP:299 | Deposition of energy leading to population decline via DNA oxidation and follicular atresia | Unclassified | - | 0.14 | KE:1115 | Increase, Reactive oxygen species |
AOP:310 | Embryonic Activation of the AHR leading to Reproductive failure, via epigenetic down-regulation of GnRHR | Unclassified | - | 0.08 | KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
AOP:311 | Deposition of energy leading to population decline via DNA oxidation and oocyte apoptosis | Unclassified | - | 0.14 | KE:1115 | Increase, Reactive oxygen species |
AOP:315 | Inhibition of JAK3 leading to impairment of T-Cell Dependent Antibody Response | Immune System Disease | Under Development | 0.4 | KE:1717 | Suppression of STAT5 binding to cytokine gene promoters |
KE:1716 | Blockade of STAT5 phosphorylation | |||||
AOP:320 | Binding of SARS-CoV-2 to ACE2 receptor leading to acute respiratory distress associated mortality | Unclassified | Under Development | 0.11 | KE:1750 | Increased inflammatory immune responses |
AOP:321 | Reduced environmental pH leading to thinner shells in Mytilus edulis | Unclassified | - | 0.18 | KE:10041 | Altered metabolic rate |
KE:10042 | Abnormal development | |||||
AOP:322 | Alkylation of DNA leading to reduced sperm count | Reproductive System Disease | - | 0.2 | KE:155 | Inadequate DNA repair |
AOP:335 | AOP for urothelial carcinogenesis due to chemical cytotoxicity by mitochondrial impairment | Cancer; Urinary System Disease | - | 0.2 | KE:795 | Increase, Regenerative cell proliferation (urothelial cells) |
AOP:346 | Aromatase inhibition leads to male-biased sex ratio via impacts on gonad differentiation | Unclassified | WPHA/WNT Endorsed | 0.4 | KE:1789 | Reduction, 17beta-estradiol synthesis by the undifferentiated gonad |
KE:1790 | Increased, Differentiation to Testis | |||||
AOP:363 | Thyroperoxidase inhibition leading to altered visual function via altered retinal layer structure | Unclassified | Under Review | 0.12 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:364 | Thyroperoxidase inhibition leading to altered visual function via decreased eye size | Unclassified | Under Development | 0.12 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:365 | Thyroperoxidase inhibition leading to altered visual function via altered photoreceptor patterning | Unclassified | Under Development | 0.12 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:374 | Binding of Sars-CoV-2 spike protein to ACE 2 receptors expressed on brain cells (neuronal and non-neuronal) leads to neuroinflammation resulting in encephalitis | Nervous System Disease | Under Development | 0.25 | KE:352 | N/A, Neurodegeneration |
AOP:376 | Androgen receptor agonism leading to male-biased sex ratio | Unclassified | WPHA/WNT Endorsed | 0.25 | KE:1790 | Increased, Differentiation to Testis |
AOP:382 | Angiotensin II type 1 receptor (AT1R) agonism leading to lung fibrosis | Musculoskeletal System Disease; Respiratory System Disease | Under Development | 0.17 | KE:1115 | Increase, Reactive oxygen species |
AOP:383 | Inhibition of Angiotensin-converting enzyme 2 leading to liver fibrosis | Gastrointestinal System Disease | Under Development | 0.17 | KE:1115 | Increase, Reactive oxygen species |
AOP:386 | Deposition of ionizing energy leading to population decline via inhibition of photosynthesis | Reproductive System Disease | - | 0.12 | KE:1115 | Increase, Reactive oxygen species |
AOP:387 | Deposition of ionising energy leading to population decline via mitochondrial dysfunction | Reproductive System Disease | - | 0.25 | KE:40 | Decrease, Mitochondrial ATP production |
KE:1115 | Increase, Reactive oxygen species | |||||
AOP:397 | Bulky DNA adducts leading to mutations | Genetic Disease | Under Development | 0.33 | KE:155 | Inadequate DNA repair |
AOP:399 | Inhibition of Fyna leading to increased mortality via decreased eye size (Microphthalmos) | Unclassified | - | 0.12 | KE:1821 | Decrease, Cell proliferation |
AOP:410 | GSK3beta inactivation leading to increased mortality via defects in developing inner ear | Unclassified | - | 0.1 | KE:1008 | Reduced, Hearing |
AOP:413 | Oxidation and antagonism of reduced glutathione leading to mortality via acute renal failure | Unclassified | - | 0.5 | KE:1115 | Increase, Reactive oxygen species |
KE:1607 | Increase, Necrosis | |||||
KE:759 | Increased, Kidney Failure | |||||
AOP:416 | Aryl hydrocarbon receptor activation leading to lung cancer through IL-6 toxicity pathway | Cancer | - | 0.17 | KE:1115 | Increase, Reactive oxygen species |
AOP:418 | Aryl hydrocarbon receptor activation leading to impaired lung function through AHR-ARNT toxicity pathway | Respiratory System Disease | - | 0.2 | KE:1115 | Increase, Reactive oxygen species |
AOP:419 | Aryl hydrocarbon receptor activation leading to impaired lung function through P53 toxicity pathway | Respiratory System Disease | - | 0.25 | KE:1262 | Apoptosis |
AOP:420 | Aryl hydrocarbon receptor activation leading to lung cancer through sustained NRF2 toxicity pathway | Cancer | - | 0.25 | KE:870 | Increase, Cell Proliferation |
AOP:432 | Deposition of Energy by Ionizing Radiation leading to Acute Myeloid Leukemia | Hematopoietic System Disease; Cancer | - | 0.27 | KE:870 | Increase, Cell Proliferation |
KE:1493 | Increased Pro-inflammatory mediators | |||||
KE:155 | Inadequate DNA repair | |||||
AOP:439 | Activation of the AhR leading to metastatic breast cancer | Thoracic Disease; Cancer | Under Development | 0.44 | KE:149 | Increase, Inflammation |
KE:1971 | Increased, tumor growth | |||||
KE:1262 | Apoptosis | |||||
KE:1241 | Increased, Motility | |||||
AOP:441 | Ionizing radiation-induced DNA damage leads to microcephaly via apoptosis and premature cell differentiation | Congenital Nervous System Abnormality; Nervous System Disease | - | 0.14 | KE:1262 | Apoptosis |
AOP:443 | DNA damage and mutations leading to Metastatic Breast Cancer | Thoracic Disease; Cancer | Under Development | 0.1 | KE:155 | Inadequate DNA repair |
AOP:450 | Inhibition of AChE and activation of CYP2E1 leading to sensory axonal peripheral neuropathy and mortality | Nervous System Disease | - | 0.14 | KE:352 | N/A, Neurodegeneration |
AOP:451 | Interaction with lung resident cell membrane components leads to lung cancer | Cancer | - | 0.33 | KE:1115 | Increase, Reactive oxygen species |
KE:1497 | Increased, recruitment of inflammatory cells | |||||
KE:870 | Increase, Cell Proliferation | |||||
AOP:452 | Adverse outcome pathway of PM-induced respiratory toxicity | Respiratory System Disease | - | 0.18 | KE:2011 | Emphysema |
KE:1262 | Apoptosis | |||||
AOP:456 | Aryl hydrocarbon receptor activation leading to early life stage mortality via sox9 repression induced cardiovascular toxicity | Unclassified | Under Review | 0.17 | KE:317 | Altered, Cardiovascular development/function |
AOP:460 | Antagonism of Smoothened receptor leading to orofacial clefting | Unclassified | Under Development | 0.22 | KE:1821 | Decrease, Cell proliferation |
KE:1262 | Apoptosis | |||||
AOP:465 | Alcohol dehydrogenase leading to reproductive dysfunction | Unclassified | - | 0.12 | KE:2050 | Increase, developmental abnormalities |
AOP:467 | Knickkopf leading to mortality | Unclassified | - | 0.11 | KE:2050 | Increase, developmental abnormalities |
AOP:470 | Deposition of energy leads to abnormal vascular remodeling | Cardiovascular System Disease | Under Review | 0.12 | KE:1493 | Increased Pro-inflammatory mediators |
AOP:480 | Mitochondrial complexes inhibition leading to heart failure via decreased ATP production | Cardiovascular System Disease; Thoracic Disease | Under Development | 0.2 | KE:40 | Decrease, Mitochondrial ATP production |
AOP:491 | Decrease, GLI1/2 target gene expression leads to orofacial clefting | Unclassified | Under Development | 0.33 | KE:1821 | Decrease, Cell proliferation |
KE:1262 | Apoptosis | |||||
AOP:493 | ERa inactivation alters AT expansion and functions and leads to insulin resistance and metabolically unhealthy obesity | Acquired Metabolic Disease | - | 0.3 | KE:1497 | Increased, recruitment of inflammatory cells |
KE:2125 | Increased fat mass | |||||
KE:2119 | Insulin resistance, increased | |||||
AOP:521 | Essential element imbalance leads to reproductive failure via oxidative stress | Unclassified | - | 0.14 | KE:1115 | Increase, Reactive oxygen species |
AOP:539 | Decreased Sodium/Potassium ATPase activity leads to Heart failure | Cardiovascular System Disease | - | 0.14 | KE:2261 | Decreased, blood plasma volume |
AOP:544 | Inhibition of neuropathy target esterase leading to delayed neuropathy via increased inflammation | Nervous System Disease | - | 0.17 | KE:149 | Increase, Inflammation |
AOP:563 | Aryl hydrocarbon Receptor (AHR) activation causes Premature Ovarian Insufficiency via Bax mediated apoptosis | Reproductive System Disease; Endocrine System Disease | - | 0.17 | KE:1262 | Apoptosis |
AOP:564 | DBDPE-induced inhibition of mitochondrial complex Ⅰ leading to population decline via neurotoxicity and metabotoxicity. | Unclassified | - | 0.09 | KE:40 | Decrease, Mitochondrial ATP production |
AOP:569 | Decreased DNA methylation of FAM50B/PTCHD3 leading to IQ loss of children via PI3K-Akt pathway | Developmental Disorder Of Mental Health | - | 0.33 | KE:1115 | Increase, Reactive oxygen species |
KE:2195 | Increase, CNS Neural cell death |
AOP Identifier | AOP Title | AO Classification | OECD Status | Coverage Score | KE Identifier | KE Name |
---|---|---|---|---|---|---|
AOP:6 | Antagonist binding to PPARα leading to body-weight loss | Symptom | WPHA/WNT Endorsed | 0.25 | KE:863 | Increased, Catabolism of Muscle Protein |
KE:864 | Decreased, Body Weight | |||||
AOP:12 | Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development leads to neurodegeneration with impairment in learning and memory in aging | Nervous System Disease; Developmental Disorder Of Mental Health | WPHA/WNT Endorsed | 0.25 | KE:341 | Impairment, Learning and memory |
KE:352 | N/A, Neurodegeneration | |||||
AOP:13 | Chronic binding of antagonist to N-methyl-D-aspartate receptors (NMDARs) during brain development induces impairment of learning and memory abilities | Developmental Disorder Of Mental Health | WPHA/WNT Endorsed | 0.1 | KE:341 | Impairment, Learning and memory |
AOP:17 | Binding of electrophilic chemicals to SH(thiol)-group of proteins and /or to seleno-proteins involved in protection against oxidative stress during brain development leads to impairment of learning and memory | Developmental Disorder Of Mental Health | WPHA/WNT Endorsed | 0.2 | KE:1493 | Increased Pro-inflammatory mediators |
KE:341 | Impairment, Learning and memory | |||||
AOP:34 | LXR activation leading to hepatic steatosis | Gastrointestinal System Disease; Inherited Metabolic Disorder | - | 0.08 | KE:345 | N/A, Liver Steatosis |
AOP:37 | PPARα activation leading to hepatocellular adenomas and carcinomas in rodents | Cancer; Gastrointestinal System Disease | Under Development | 0.4 | KE:719 | Increase, hepatocellular adenomas and carcinomas |
KE:716 | Increase, cell proliferation (hepatocytes) | |||||
AOP:42 | Inhibition of Thyroperoxidase and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive Disorder | WPHA/WNT Endorsed | 0.25 | KE:277 | Thyroid hormone synthesis, Decreased |
KE:402 | Cognitive function, decreased | |||||
AOP:43 | Disruption of VEGFR Signaling Leading to Developmental Defects | Unclassified | WPHA/WNT Endorsed | 0.4 | KE:28 | Reduction, Angiogenesis |
KE:1001 | Increased, Developmental Defects | |||||
AOP:48 | Binding of agonists to ionotropic glutamate receptors in adult brain causes excitotoxicity that mediates neuronal cell death, contributing to learning and memory impairment. | Developmental Disorder Of Mental Health | WPHA/WNT Endorsed | 0.22 | KE:341 | Impairment, Learning and memory |
KE:352 | N/A, Neurodegeneration | |||||
AOP:54 | Inhibition of Na+/I- symporter (NIS) leads to learning and memory impairment | Developmental Disorder Of Mental Health | WPHA/WNT Endorsed | 0.2 | KE:277 | Thyroid hormone synthesis, Decreased |
KE:341 | Impairment, Learning and memory | |||||
AOP:107 | Constitutive androstane receptor activation leading to hepatocellular adenomas and carcinomas in the mouse and the rat | Cancer; Gastrointestinal System Disease | Under Review | 0.4 | KE:719 | Increase, hepatocellular adenomas and carcinomas |
KE:716 | Increase, cell proliferation (hepatocytes) | |||||
AOP:108 | Inhibition of pyruvate dehydrogenase kinase leading to hepatocellular adenomas and carcinomas (in mouse and rat) | Cancer; Gastrointestinal System Disease | - | 0.33 | KE:768 | Increase, Cytotoxicity |
KE:719 | Increase, hepatocellular adenomas and carcinomas | |||||
AOP:117 | Androgen receptor activation leading to hepatocellular adenomas and carcinomas (in mouse and rat) | Cancer; Gastrointestinal System Disease | Under Development | 0.5 | KE:719 | Increase, hepatocellular adenomas and carcinomas |
KE:716 | Increase, cell proliferation (hepatocytes) | |||||
AOP:134 | Sodium Iodide Symporter (NIS) Inhibition and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive Disorder | - | 0.22 | KE:277 | Thyroid hormone synthesis, Decreased |
KE:402 | Cognitive function, decreased | |||||
AOP:139 | Alkylation of DNA leading to cancer 1 | Cancer | - | 0.5 | KE:885 | Increase, Cancer |
KE:155 | Inadequate DNA repair | |||||
AOP:196 | Volatile Organic Chemicals Activate TRPA1 Receptor to Induce Sensory Pulmonary Irritation | Respiratory System Disease | - | 0.11 | KE:1226 | Increased Respiratory irritability and Chronic Cough, |
AOP:203 | 5-hydroxytryptamine transporter inhibition leading to decreased reproductive success and population decline | Reproductive System Disease | - | 0.12 | KE:1141 | Decreased, Reproductive Success |
AOP:205 | AOP from chemical insult to cell death | Unclassified | - | 0.33 | KE:1263 | Necrosis |
KE:1262 | Apoptosis | |||||
AOP:220 | Cyp2E1 Activation Leading to Liver Cancer | Cancer; Gastrointestinal System Disease | WPHA/WNT Endorsed | 0.6 | KE:1393 | Hepatocytotoxicity |
KE:1394 | Induction, persistent proliferation/sustained proliferation | |||||
KE:1395 | Liver Cancer | |||||
AOP:227 | NSAID induced PTGS1 inactivation to gastric ulcer | Gastrointestinal System Disease | - | 0.14 | KE:1385 | Activated, gastric ulcer formation |
AOP:228 | NSAID induced PTGS2 inactivation to gastric ulcer | Gastrointestinal System Disease | - | 0.2 | KE:1385 | Activated, gastric ulcer formation |
AOP:260 | CYP2E1 activation and formation of protein adducts leading to neurodegeneration | Nervous System Disease | - | 0.14 | KE:1514 | Neurodegeneration |
AOP:269 | Elevated ATP demand for detoxification and repair mechanisms leading to impaired growth and development | Unclassified | - | 0.17 | KE:10013 | Impaired growth and development |
AOP:278 | IKK complex inhibition leading to liver injury | Unclassified | - | 0.12 | KE:1549 | Liver Injury |
AOP:281 | Acetylcholinesterase Inhibition Leading to Neurodegeneration | Nervous System Disease | - | 0.1 | KE:352 | N/A, Neurodegeneration |
AOP:293 | Increased DNA damage leading to increased risk of breast cancer | Genetic Disease; Thoracic Disease; Cancer | Under Development | 0.33 | KE:1493 | Increased Pro-inflammatory mediators |
KE:1193 | N/A, Breast Cancer | |||||
KE:1182 | Increase, Cell Proliferation (Epithelial Cells) | |||||
AOP:294 | Increased reactive oxygen and nitrogen species (RONS) leading to increased risk of breast cancer | Genetic Disease; Thoracic Disease; Cancer | Under Development | 0.33 | KE:1493 | Increased Pro-inflammatory mediators |
KE:1193 | N/A, Breast Cancer | |||||
KE:1182 | Increase, Cell Proliferation (Epithelial Cells) | |||||
AOP:300 | Thyroid Receptor Antagonism and Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive Disorder | Under Development | 0.2 | KE:402 | Cognitive function, decreased |
AOP:304 | TBX1 inhibition leading to congenital cardiac conotruncal anomalies | Cardiovascular System Disease | - | 0.17 | KE:1685 | Anomalies, Congenital cardiac conotruncal |
AOP:362 | Immune mediated hepatitis | Gastrointestinal System Disease; Immune System Disease | - | 0.12 | KE:1820 | Immune mediated hepatitis |
AOP:379 | Binding to ACE2 leading to thrombosis and disseminated intravascular coagulation | Cardiovascular System Disease | Under Development | 0.29 | KE:1869 | Diminished protective oxidative stress response |
KE:1846 | Thrombosis and Disseminated Intravascular Coagulation | |||||
AOP:384 | Hyperactivation of ACE/Ang-II/AT1R axis leading to chronic kidney disease | Urinary System Disease | - | 0.33 | KE:1115 | Increase, Reactive oxygen species |
KE:1603 | Chronic kidney disease | |||||
AOP:392 | Decreased fibrinolysis and activated bradykinin system leading to hyperinflammation | Unclassified | Under Development | 0.4 | KE:1868 | Hyperinflammation |
KE:1497 | Increased, recruitment of inflammatory cells | |||||
AOP:405 | Organo-Phosphate Chemicals induced inhibition of AChE leading to impaired cognitive function | Cognitive Disorder | - | 0.2 | KE:402 | Cognitive function, decreased |
AOP:406 | SARS-CoV-2 infection leading to hyperinflammation | Unclassified | - | 0.33 | KE:1868 | Hyperinflammation |
KE:1869 | Diminished protective oxidative stress response | |||||
AOP:431 | Increased tumor necrosis factor (TNF) leading to increased risk of gestational diabetes mellitus (GDM) | Inherited Metabolic Disorder | - | 0.4 | KE:1953 | Gestational diabetes mellitus |
KE:1952 | Abnormal, Glucose homeostasis | |||||
AOP:433 | hERG channel blockade leading to sudden cardiac death | Cardiovascular System Disease | - | 0.17 | KE:1964 | Sudden cardiac death |
AOP:442 | Binding to voltage gate sodium channels during development leads to cognitive impairment | Cognitive Disorder | Under Review | 0.14 | KE:402 | Cognitive function, decreased |
AOP:447 | Kidney failure induced by inhibition of mitochondrial electron transfer chain through apoptosis, inflammation and oxidative stress pathways | Urinary System Disease | - | 0.08 | KE:759 | Increased, Kidney Failure |
AOP:457 | Succinate dehydrogenase inhibition leading to increased insulin resistance through reduction in circulating thyroxine | Inherited Metabolic Disorder | - | 0.33 | KE:277 | Thyroid hormone synthesis, Decreased |
KE:2119 | Insulin resistance, increased | |||||
AOP:458 | AhR activation in the liver leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive Disorder | - | 0.12 | KE:402 | Cognitive function, decreased |
AOP:459 | AhR activation in the thyroid leading to Subsequent Adverse Neurodevelopmental Outcomes in Mammals | Cognitive Disorder | - | 0.22 | KE:277 | Thyroid hormone synthesis, Decreased |
KE:402 | Cognitive function, decreased | |||||
AOP:468 | Binding of SARS-CoV-2 to ACE2 leads to hyperinflammation (via cell death) | Unclassified | - | 0.25 | KE:1868 | Hyperinflammation |
KE:1497 | Increased, recruitment of inflammatory cells | |||||
AOP:474 | Succinate dehydrogenase inactivation leads to cancer by promoting EMT | Cancer | Under Development | 0.2 | KE:885 | Increase, Cancer |
AOP:475 | Binding of chemicals to ionotropic glutamate receptors leads to impairment of learning and memory via loss of drebrin from dendritic spines of neurons | Developmental Disorder Of Mental Health | Under Development | 0.12 | KE:341 | Impairment, Learning and memory |
AOP:478 | Deposition of energy leading to occurrence of cataracts | Nervous System Disease; Monogenic Disease | Under Review | 0.3 | KE:870 | Increase, Cell Proliferation |
KE:155 | Inadequate DNA repair | |||||
KE:2083 | Occurrence of Cataracts | |||||
AOP:483 | Deposition of Energy Leading to Learning and Memory Impairment | Developmental Disorder Of Mental Health | Under Review | 0.12 | KE:341 | Impairment, Learning and memory |
AOP:485 | Thyroid hormone antagonism leading to impaired oligodendrocyte maturation during development and subsequent decreased cognition | Cognitive Disorder | - | 0.14 | KE:402 | Cognitive function, decreased |
AOP:486 | Binding to the extracellular protein laminin leading to decreased cognitive function | Cognitive Disorder | - | 0.14 | KE:402 | Cognitive function, decreased |
AOP:490 | Co-activation of IP3R and RyR leads to reduced IQ through non-cholinergic mechanisms | Developmental Disorder Of Mental Health | - | 0.09 | KE:341 | Impairment, Learning and memory |
AOP:495 | Androgen receptor activation leading to prostate cancer | Reproductive System Disease; Cancer | - | 0.33 | KE:854 | Alterations, Cellular proliferation / hyperplasia |
KE:1183 | Decreased, Apoptosis (Epithelial Cells) | |||||
KE:2135 | Prostate cancer | |||||
AOP:497 | ERa inactivation alters mitochondrial functions and insulin signalling in skeletal muscle and leads to insulin resistance and metabolic syndrome | Inherited Metabolic Disorder; Disease Of Metabolism | - | 0.38 | KE:1115 | Increase, Reactive oxygen species |
KE:2145 | Metabolic syndrome | |||||
KE:2119 | Insulin resistance, increased | |||||
AOP:498 | Increased LCN2/iron complex leading to neurological disorders | Nervous System Disease | - | 0.75 | KE:2149 | Increased intracelluar Iron accumulation |
KE:191 | Neuronal dysfunction | |||||
KE:2150 | Neurological disorder | |||||
AOP:499 | Activation of MEK-ERK1/2 leads to deficits in learning and cognition via disrupted neurotransmitter release | Developmental Disorder Of Mental Health | - | 0.25 | KE:341 | Impairment, Learning and memory |
AOP:500 | Activation of MEK-ERK1/2 leads to deficits in learning and cognition via ROS and apoptosis | Developmental Disorder Of Mental Health | - | 0.57 | KE:1115 | Increase, Reactive oxygen species |
KE:1262 | Apoptosis | |||||
KE:341 | Impairment, Learning and memory | |||||
KE:352 | N/A, Neurodegeneration | |||||
AOP:507 | Nrf2 inhibition leading to vascular disrupting effects via inflammation pathway | Cardiovascular System Disease | - | 0.17 | KE:2161 | Increase, Vascular disrupting effects |
AOP:508 | Nrf2 inhibition leading to vascular disrupting effects through activating HIF1α, Semaphorin 6A, and Dll4-Notch pathway | Cardiovascular System Disease | - | 0.14 | KE:2161 | Increase, Vascular disrupting effects |
AOP:509 | Nrf2 inhibition leading to vascular disrupting effects through activating apoptosis signal pathway and mitochondrial dysfunction | Cardiovascular System Disease | - | 0.14 | KE:2161 | Increase, Vascular disrupting effects |
AOP:510 | Demethylation of PPAR promotor leading to vascular disrupting effects | Cardiovascular System Disease | - | 0.1 | KE:2161 | Increase, Vascular disrupting effects |
AOP:520 | Retinoic acid receptor agonism during neurodevelopment leading to impaired learning and memory | Developmental Disorder Of Mental Health | - | 0.2 | KE:341 | Impairment, Learning and memory |
AOP:525 | Reduced oligodendrocyte differentiation during neurodevelopment leading to impaired learning and memory | Developmental Disorder Of Mental Health | - | 0.15 | KE:2115 | Altered, cholesterol metabolism |
KE:341 | Impairment, Learning and memory | |||||
AOP:533 | Retinoic acid receptor antagonism during neurodevelopment leading to impaired learning and memory | Developmental Disorder Of Mental Health | - | 0.17 | KE:341 | Impairment, Learning and memory |
AOP:534 | Succinate dehydrogenase (SDH) inhibition leads to cancer through oxidative stress | Cancer | - | 0.5 | KE:1115 | Increase, Reactive oxygen species |
KE:885 | Increase, Cancer | |||||
KE:1446 | Decrease, Coupling of oxidative phosphorylation | |||||
AOP:535 | Binding and activation of GPER leading to learning and memory impairments | Developmental Disorder Of Mental Health | - | 0.22 | KE:1262 | Apoptosis |
KE:341 | Impairment, Learning and memory | |||||
AOP:546 | Succinate dehydrogenase inactivation leads to cancer through hypoxic-like mechanisms | Cancer | - | 0.2 | KE:885 | Increase, Cancer |
AOP:551 | Increased Muscarinic M2 Receptor leading to Arrhythmia | Symptom | - | 0.2 | KE:1106 | Occurrence, cardiac arrhythmia |
AOP:554 | β-adrenergic receptor agonists leading to arrhythmias. | Symptom | - | 0.25 | KE:1106 | Occurrence, cardiac arrhythmia |
AOP:559 | Inhibition of acetylcholinesterase (AChE) leading to arrhythmias | Symptom | - | 0.2 | KE:1106 | Occurrence, cardiac arrhythmia |
AOP:560 | Inhibition of Funny current (If) leading to Arrhythmias | Symptom | - | 0.25 | KE:1106 | Occurrence, cardiac arrhythmia |
AOP:562 | HCN Channel Inhibition leading to Arrhythmias | Symptom | - | 0.2 | KE:1106 | Occurrence, cardiac arrhythmia |
AOP Identifier | AOP Title | AO Classification | OECD Status | Coverage Score | KE Identifier | KE Name |
---|---|---|---|---|---|---|
AOP:38 | Protein Alkylation leading to Liver Fibrosis | Gastrointestinal System Disease | WPHA/WNT Endorsed | 0.29 | KE:1493 | Increased Pro-inflammatory mediators |
KE:244 | Alkylation, Protein | |||||
AOP:62 | AKT2 activation leading to hepatic steatosis | Gastrointestinal System Disease; Inherited Metabolic Disorder | - | 0.25 | KE:486 | systemic inflammation leading to hepatic steatosis |
AOP:121 | Urinary bladder calculi leading to urothelial papillomas and carcinomas (in mouse and rat) | Cancer; Urinary System Disease | - | 0.4 | KE:795 | Increase, Regenerative cell proliferation (urothelial cells) |
KE:793 | Increase, Urinary bladder calculi | |||||
AOP:128 | Kidney dysfunction by decreased thyroid hormone | Urinary System Disease | Under Development | 0.09 | KE:277 | Thyroid hormone synthesis, Decreased |
AOP:209 | Perturbation of cholesterol and glutathione homeostasis leading to hepatotoxicity: Integrated multi-OMICS approach for building AOP | Gastrointestinal System Disease | - | 0.38 | KE:1287 | Glutathione synthesis |
KE:1289 | Perturbation of cholesterol | |||||
KE:1286 | Down Regulation, GSS and GSTs gene | |||||
AOP:258 | Renal protein alkylation leading to kidney toxicity | Urinary System Disease | Under Development | 0.4 | KE:40 | Decrease, Mitochondrial ATP production |
KE:244 | Alkylation, Protein | |||||
AOP:263 | Uncoupling of oxidative phosphorylation leading to growth inhibition via decreased cell proliferation | Unclassified | WPHA/WNT Endorsed | 0.75 | KE:1821 | Decrease, Cell proliferation |
KE:1771 | Decrease, Adenosine triphosphate pool | |||||
KE:1446 | Decrease, Coupling of oxidative phosphorylation | |||||
AOP:264 | Uncoupling of oxidative phosphorylation leading to growth inhibition via ATP depletion associated cell death | Unclassified | Under Development | 0.5 | KE:1771 | Decrease, Adenosine triphosphate pool |
KE:1446 | Decrease, Coupling of oxidative phosphorylation | |||||
AOP:265 | Uncoupling of oxidative phosphorylation leading to growth inhibition via increased cytosolic calcium | Unclassified | Under Development | 0.25 | KE:1446 | Decrease, Coupling of oxidative phosphorylation |
AOP:266 | Uncoupling of oxidative phosphorylation leading to growth inhibition via decreased Na-K ATPase activity | Unclassified | Under Development | 0.33 | KE:1771 | Decrease, Adenosine triphosphate pool |
KE:1446 | Decrease, Coupling of oxidative phosphorylation | |||||
AOP:267 | Uncoupling of oxidative phosphorylation leading to growth inhibition via glucose depletion | Unclassified | Under Development | 0.4 | KE:1821 | Decrease, Cell proliferation |
KE:1446 | Decrease, Coupling of oxidative phosphorylation | |||||
AOP:268 | Uncoupling of oxidative phosphorylation leading to growth inhibition via mitochondrial swelling | Unclassified | Under Development | 0.25 | KE:1446 | Decrease, Coupling of oxidative phosphorylation |
AOP:282 | Adverse outcome pathway on photochemical toxicity initiated by light exposure | Unclassified | Under Review | 0.25 | KE:1115 | Increase, Reactive oxygen species |
AOP:298 | Increase in reactive oxygen species (ROS) leading to human treatment-resistant gastric cancer via chronic ROS | Cancer; Gastrointestinal System Disease | Under Review | 0.33 | KE:1115 | Increase, Reactive oxygen species |
KE:1753 | Chronic reactive oxygen species | |||||
AOP:303 | Frustrated phagocytosis-induced lung cancer | Cancer | Under Development | 0.57 | KE:1115 | Increase, Reactive oxygen species |
KE:870 | Increase, Cell Proliferation | |||||
KE:1497 | Increased, recruitment of inflammatory cells | |||||
KE:1668 | Frustrated phagocytosis | |||||
AOP:324 | Excessive reactive oxygen species leading to growth inhibition via oxidative DNA damage and cell death | Unclassified | - | 0.25 | KE:1115 | Increase, Reactive oxygen species |
AOP:325 | Excessive reactive oxygen species leading to growth inhibition via lipid peroxidation and cell death | Unclassified | - | 0.25 | KE:1115 | Increase, Reactive oxygen species |
AOP:326 | Excessive reactive oxygen species leading to growth inhibition via protein oxidation and cell death | Unclassified | - | 0.25 | KE:1115 | Increase, Reactive oxygen species |
AOP:327 | Excessive reactive oxygen species production leading to mortality (1) | Unclassified | - | 0.4 | KE:1115 | Increase, Reactive oxygen species |
KE:1769 | Increase, Body fluid overload | |||||
AOP:328 | Excessive reactive oxygen species production leading to mortality (2) | Unclassified | - | 0.4 | KE:1115 | Increase, Reactive oxygen species |
KE:1771 | Decrease, Adenosine triphosphate pool | |||||
AOP:329 | Excessive reactive oxygen species production leading to mortality (3) | Unclassified | - | 0.4 | KE:1115 | Increase, Reactive oxygen species |
KE:1771 | Decrease, Adenosine triphosphate pool | |||||
AOP:330 | Excessive reactive oxygen species production leading to mortality (4) | Unclassified | - | 0.2 | KE:1115 | Increase, Reactive oxygen species |
AOP:331 | Excessive reactive oxygen species leading to growth inhibition via oxidative DNA damage and reduced cell proliferation | Unclassified | - | 0.5 | KE:1821 | Decrease, Cell proliferation |
KE:1115 | Increase, Reactive oxygen species | |||||
KE:1505 | Cell cycle, disrupted | |||||
AOP:332 | Excessive reactive oxygen species leading to growth inhibition via lipid peroxidation and reduced cell proliferation | Unclassified | - | 0.6 | KE:1821 | Decrease, Cell proliferation |
KE:1115 | Increase, Reactive oxygen species | |||||
KE:1505 | Cell cycle, disrupted | |||||
AOP:333 | Excessive reactive oxygen species leading to growth inhibition via uncoupling of oxidative phosphorylation | Unclassified | - | 0.8 | KE:1821 | Decrease, Cell proliferation |
KE:1115 | Increase, Reactive oxygen species | |||||
KE:1771 | Decrease, Adenosine triphosphate pool | |||||
KE:1446 | Decrease, Coupling of oxidative phosphorylation | |||||
AOP:423 | Toxicological mechanisms of hepatocyte apoptosis through the PARP1 dependent cell death pathway | Unclassified | - | 0.17 | KE:1115 | Increase, Reactive oxygen species |
AOP:438 | reactive oxygen species generation leading to increased cardiovascular morbidity and mortality | Cardiovascular System Disease | - | 0.25 | KE:1115 | Increase, Reactive oxygen species |
KE:1926 | Increased, Vascular fibrosis | |||||
KE:1919 | Increased, Cardiac Dysregulation | |||||
AOP:446 | PM-related Adverse outcome pathway frameworks on various systems | Respiratory System Disease | - | 0.25 | KE:1262 | Apoptosis |
KE:149 | Increase, Inflammation | |||||
KE:1115 | Increase, Reactive oxygen species | |||||
KE:1497 | Increased, recruitment of inflammatory cells | |||||
KE:1198 | Activation, Macrophages | |||||
AOP:448 | ROS, inflammation, and activation of nAChR lead to increased incidence of cardiovascular morbidity and mortality | Cardiovascular System Disease | - | 0.18 | KE:1115 | Increase, Reactive oxygen species |
KE:2001 | Cardiac hypertrophy | |||||
KE:1198 | Activation, Macrophages | |||||
AOP:453 | Reactive oxygen species and subsequent oxidative stress lead to increased incidence of digestive morbidity and mortality in the general population | Gastrointestinal System Disease | - | 0.15 | KE:1115 | Increase, Reactive oxygen species |
KE:1198 | Activation, Macrophages | |||||
AOP:469 | Reactive oxygen speicies overproduction leading to increased digestive morbidity and mortality in generation population | Gastrointestinal System Disease | - | 0.15 | KE:1115 | Increase, Reactive oxygen species |
KE:1198 | Activation, Macrophages | |||||
AOP:492 | Glutathione conjugation leading to reproductive dysfunction via oxidative stress | Reproductive System Disease | - | 0.4 | KE:1115 | Increase, Reactive oxygen species |
KE:2131 | Conjugation, GSH | |||||
AOP:540 | Oxidative Stress in the Fish Ovary Leads to Reproductive Impairment via Reduced Vitellogenin Production | Unclassified | - | 0.33 | KE:3 | Reduction, 17beta-estradiol synthesis by ovarian granulosa cells |
KE:1115 | Increase, Reactive oxygen species | |||||
KE:1262 | Apoptosis | |||||
AOP:541 | Excessive ROS generation leading to increased incidence of vascular calcification by VSMC phenotype switching | Cardiovascular System Disease | - | 0.31 | KE:1115 | Increase, Reactive oxygen species |
KE:1816 | Mitochondrial dysfunction EMPTY | |||||
KE:1493 | Increased Pro-inflammatory mediators | |||||
KE:1198 | Activation, Macrophages |
AOP Identifier | AOP Title | AO Classification | OECD Status | Coverage Score | KE Identifier | KE Name |
---|---|---|---|---|---|---|
AOP:118 | Chronic cytotoxicity leading to hepatocellular adenomas and carcinomas (in mouse and rat) | Cancer; Gastrointestinal System Disease | - | 0.75 | KE:719 | Increase, hepatocellular adenomas and carcinomas |
KE:786 | Increase, Cytotoxicity (hepatocytes) | |||||
KE:787 | Increase, Regenerative cell proliferation (hepatocytes) | |||||
AOP:409 | Frustrated phagocytosis leads to malignant mesothelioma | Cancer | - | 0.62 | KE:870 | Increase, Cell Proliferation |
KE:1668 | Frustrated phagocytosis | |||||
KE:1115 | Increase, Reactive oxygen species | |||||
KE:1497 | Increased, recruitment of inflammatory cells | |||||
KE:1090 | Increased, mesotheliomas | |||||
AOP:463 | The AOP framwork on silica nanopariticles induced hepatoxicity | Gastrointestinal System Disease | - | 0.36 | KE:149 | Increase, Inflammation |
KE:1115 | Increase, Reactive oxygen species | |||||
KE:1262 | Apoptosis | |||||
KE:2034 | liver dysfunction | |||||
AOP:472 | DNA adduct formation leading to kidney failure | Urinary System Disease | - | 0.44 | KE:149 | Increase, Inflammation |
KE:1115 | Increase, Reactive oxygen species | |||||
KE:1816 | Mitochondrial dysfunction EMPTY | |||||
KE:759 | Increased, Kidney Failure | |||||
AOP:488 | Increased reactive oxygen species production leading to decreased cognitive function | Cognitive Disorder | - | 0.43 | KE:1115 | Increase, Reactive oxygen species |
KE:1869 | Diminished protective oxidative stress response | |||||
KE:402 | Cognitive function, decreased | |||||
AOP:501 | Excessive iron accumulation leading to neurological disorders | Nervous System Disease | - | 0.5 | KE:2149 | Increased intracelluar Iron accumulation |
KE:2150 | Neurological disorder | |||||
AOP:505 | Reactive Oxygen Species (ROS) formation leads to cancer via inflammation pathway | Cancer | - | 0.6 | KE:149 | Increase, Inflammation |
KE:1115 | Increase, Reactive oxygen species | |||||
KE:885 | Increase, Cancer | |||||
AOP:511 | The AOP framework on ROS-mediated oxidative stress induced vascular disrupting effects | Cardiovascular System Disease | - | 0.12 | KE:1115 | Increase, Reactive oxygen species |
KE:2161 | Increase, Vascular disrupting effects | |||||
AOP:513 | Reactive Oxygen (ROS) formation leads to cancer via Peroxisome proliferation-activated receptor (PPAR) pathway | Cancer | - | 0.6 | KE:1115 | Increase, Reactive oxygen species |
KE:1060 | Alteration, lipid metabolism | |||||
KE:885 | Increase, Cancer |
TICToK is a database of tattoo ink chemicals compiled from different regulatory resources. The authors are not liable for any inaccuracies or omissions of any chemicals in this resource. Importantly, our sole goal to build this resource on tattoo ink chemicals is to enable future basic research on this topic, and it does not necessarily reflect the views or objectives of our employers or funders.